Sarepta Therapeutics (NASDAQ:SRPT – Get Rating)'s stock had its "outperform" rating reaffirmed by stock analysts at SVB Leerink in a research note issued on Friday, Benzinga reports. They presently have a $160.00 price objective on the biotechnology company's stock. SVB Leerink's price objective points to a potential upside of 22.87% from the stock's previous close.
Several other analysts have also issued reports on SRPT. BTIG Research boosted their target price on Sarepta Therapeutics from $125.00 to $160.00 and gave the company a "buy" rating in a research note on Thursday, December 22nd. StockNews.com initiated coverage on Sarepta Therapeutics in a research note on Wednesday, October 12th. They issued a "hold" rating on the stock. UBS Group upgraded Sarepta Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the company from $100.00 to $158.00 in a research note on Friday, December 16th. Cowen boosted their target price on Sarepta Therapeutics from $114.00 to $125.00 in a research note on Wednesday, January 11th. Finally, Royal Bank of Canada lowered their target price on Sarepta Therapeutics from $193.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday, November 3rd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $150.14.
Get Sarepta Therapeutics alerts:Sarepta Therapeutics Price Performance
Shares of SRPT opened at $130.22 on Friday. Sarepta Therapeutics has a 1 year low of $61.28 and a 1 year high of $134.08. The company has a debt-to-equity ratio of 3.58, a current ratio of 4.36 and a quick ratio of 3.99. The company has a market capitalization of $11.43 billion, a price-to-earnings ratio of -15.86 and a beta of 1.04. The business has a 50-day moving average of $121.96 and a 200-day moving average of $110.67.
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last issued its earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share for the quarter, missing analysts' consensus estimates of ($1.21) by ($1.73). The business had revenue of $230.30 million during the quarter, compared to the consensus estimate of $234.55 million. Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net margin of 81.76%. The company's revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. As a group, equities research analysts anticipate that Sarepta Therapeutics will post -8.19 earnings per share for the current year.Insider Activity at Sarepta Therapeutics
In related news, Director Stephen Mayo sold 858 shares of the firm's stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $109.92, for a total transaction of $94,311.36. Following the completion of the transaction, the director now owns 6,387 shares of the company's stock, valued at approximately $702,059.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.40% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Sarepta Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. Harbor Capital Advisors Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter valued at about $296,000. Asset Dedication LLC bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $65,000. Perfromance Wealth Partners LLC bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $207,000. Calton & Associates Inc. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $209,000. Finally, Maryland State Retirement & Pension System bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $828,000. 87.31% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
(Get Rating)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
Featured Articles
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.